Project | Area | Stage |
---|---|---|
Fosfestrol | Uro-oncology - Prostate Cancer | Pre-registration |
Calbi | Gastro-enterology - Bile Acid Diarrhea | Pre-clinical development |
MCC | Pharmaceutical Technology - Excipients | Partnering |
Buruli FDC | Tropical diseases - Buruli | Formulation |
Metronidazole MR | Gastro-enterology - Pouchitis | Clinical development |
Oxytone Sublingual | Gynaecology - Postpartum hemmorrhage | Clinical development |
Avivia is open to evaluate any partnering proposition, whether it is related to one of our internal development programs listed in the table above, or whether it is related to a product program suggested by a third party for co-development. We favor synergistic partnerships aimed at accelerating the development process and at expanding commercial opportunities with win-win for all parties involved.
If you are interested to learn more about one of our proprietary development programs or if you have a partnering opportunity you would like to discuss further, please don’t hesitate and get in contact with our business development and partnering team!
Hans Platteeuw, CEO Avivia
Avivia BV – (headquarters & R&D facilities)
Novio Tech Campus – M-building
Transistorweg 5
6534 AT Nijmegen, The Netherlands
Email
info[at] avivia.nl